Protein drugs to treat multiple sclerosis (ABN 101): next-generation Interferon-beta agent

Interferon-beta is a drug for first-line treatment of multiple sclerosis. ABN 101 is a candidate drug material under development for drugs that improve patient convenience and cost-competitiveness to fulfill unmet medical needs.

Description on Technology Applied

-The next generation Biobetter version of the Interferon-beta induces glycosylation through a change in the aminoacid sequence of human Interferon-beta.
 
-IP secured in 21 countries, including the United States and European countries.
 
 

Differentiating characteristics of ABN 101

  • Decrease of aggregation tendency with additional glycosylation
  • Improvement of solubility and stability
  • Price rationalization through improved productivity
  • Increase of in-vivo half-life and activity
  • Maximizing the drug effect by using the pharmacodynamics biomarker and companion diagnostics
  • Possibility of use in the off-label market, such as to treat viral disease

 

Current development stage

  • Process development in conjunction with a cross-ministry new drug development project
 

Target indication

  • First line Tx for relapsing remitting multiple sclerosis (RRMS) & Clinically isolated syndrome(CIS)
 

Development goals and strategies 

  • European Medicines Agency (EMA) approved
  • Indication expansion to drug for viral disease
 

Patents

  • Human Interferon-beta Mutein (BR, CN, EP, IN, JP, KR, PCT, US)
  • Modified Interferon-beta Conjugated with Polyethylene Glycol (KR, PCT)
  • Stabilized Formulations of Interferon beta Mutant (KR, PCT)
  • ImmunocytokineConjugated with Human Interferon Beta-mutein and Method for Preparing Thereof (KR, PCT)